
Organogenesis Holdings (ORGO) Stock Forecast & Price Target
Organogenesis Holdings (ORGO) Analyst Ratings
Bulls say
Organogenesis Holdings Inc has been navigating mixed performance influenced by market dynamics and impending changes in reimbursement structures, yet the company is positioned to achieve solid results that could lead to improved valuations. The final reimbursement rate for CY2026 was set at $127.28/cm², slightly above initial proposals, indicating a favorable environment that may enhance operating profits over time. Furthermore, as the market consolidates, Organogenesis is expected to capture increased market share, leading to further gains in stock performance against a backdrop of trading below its peers.
Bears say
Organogenesis Holdings Inc. faces a negative outlook primarily due to anticipated stagnation in fiscal year 2026, impacted by elevated research and development costs and the uncertainty surrounding potential reductions in selling, general, and administrative expenses. The company is also at risk of lower-than-expected growth in its PuraPly product line, challenges related to Medicare Part B pricing, and increased competition that could hinder market share gains due to regulatory complexities. Furthermore, anticipated difficulties with new product uptake, alongside negative clinical outcomes and the overall economic environment affecting sales forces, contribute to a declining confidence in the company's future financial performance.
This aggregate rating is based on analysts' research of Organogenesis Holdings and is not a guaranteed prediction by Public.com or investment advice.
Organogenesis Holdings (ORGO) Analyst Forecast & Price Prediction
Start investing in Organogenesis Holdings (ORGO)
Order type
Buy in
Order amount
Est. shares
0 shares